Page last updated: 2024-11-05

phenazocine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenazocine: An opioid analgesic with actions and uses similar to MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1095) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14707
CHEMBL ID46399
SCHEMBL ID26733
MeSH IDM0016492

Synonyms (29)

Synonym
6,11-dimethyl-1,2,3,4,5,6-hexahydro-8-hydroxy-3-phenethyl-2,6-methano-3-benzazocine
2'-hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocin-8-ol
skf 6574
fenazocina [inn-spanish]
nih 7519
phenazocinum [inn-latin]
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-phenethyl-
phenethylazocine
prinadol
1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocine
dea no. 9715
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-phenylethyl)-
127-35-5
phenazocine
phenobenzorphan
CHEMBL46399 ,
ids-np-008
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-phenylethyl)-2,6-methano-3-benzazocin-8-ol
6,11-dimethyl-3-phenethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(phenazocine)
bdbm50027791
phenazocinum
phenazocine [inn:ban]
fenazocina
SCHEMBL26733
ZQHYKVKNPWDQSL-UHFFFAOYSA-N
DTXSID90860736
1,13-dimethyl-10-(2-phenylethyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
Q7181332

Research Excerpts

Actions

ExcerptReferenceRelevance
"Phenazocine does not cause spasm of the sphincter of Oddi and so is recommended for treating biliary or pancreatic pain."( Double-blind clinical trial of the analgesic effects of phenazocine hydrobromide (Narphen) compared with morphine sulphate in patients with acute abdominal pain.
Hopton, D, 1971
)
1.22

Toxicity

ExcerptReferenceRelevance
"3 microM and 9 microM, respectively, against the toxic action of 100 microM glutamate."( Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: protection by SKF 10,047.
Feuerstein, G; Lysko, PG, 1990
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
" The STR was mimicked in mice treated with BD 1047 (a putative σ(1) receptor antagonist), but not SM-21, a putative σ(2) receptor antagonist, in combination with METH."( Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine.
Hall, FS; Kitanaka, J; Kitanaka, N; Nishiyama, N; Takemura, M; Tanaka, K; Uhl, GR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"L-745,870,(3-([4-(4-chlorophenyl)piperazin-1-yl]methyl)-1H- pyrollo[2,3-b] pyridine, was identified as a selective dopamine D4 receptor antagonist with excellent oral bioavailability and brain penetration."( Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
Baskin, E; Bristow, LJ; Chapman, KL; Curtis, N; Emms, F; Fletcher, AE; Freedman, S; Graham, M; Knowles, M; Kulagowski, JJ; Leeson, PD; Lynch, JJ; Marwood, R; Matheson, S; Mcallister, G; Myers, J; Patel, S; Ragan, CI; Rathbone, D; Ridgill, M; Rupniak, NM; Watt, AP, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" When ischemic animals were administered the multiple dosing regimen of (+)SKF 10,047, no hypothermic effect was noted in the temporalis muscle over 4 hours' postischemia."( Neuroprotective effects of SKF 10,047 in cultured rat cerebellar neurons and in gerbil global brain ischemia.
Feuerstein, G; Gagnon, RC; Gu, JL; Lysko, PG; Yue, TL, 1992
)
0.28
" These results were confirmed by studies employing a self- and cross-displacement design and dose-response surfaces for SKF and TCP, with and without blockade by haloperidol of the sigma site."( Quantitative characterization of multiple binding sites for phencyclidine and N-allylnormetazocine in membranes from rat and guinea pig brain.
Katki, AG; Munson, PJ; Rodbard, D; Schwarz, S; Zhou, GZ, 1991
)
0.28
" In Long-Evans rats, BW942C produced a biphasic dose-response curve for urine output with lower doses increasing and higher doses suppressing output."( Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vitro studies in humans and animals.
Cone, EJ; Johnson, RE; Su, TP; Vaupel, DB, 1990
)
0.28
" This property was reflected by a greater extent of inhibition of the binding of PCP-selective relative to sigma H-selective ligands at a given cation concentration, as well as by lower IC50's and by steeper slopes of the cation dose-response curves."( Differential modulation by cations of sigma and phencyclidine binding sites in rat brain.
Katki, AG; Rodbard, D; Schwarz, S; Zhou, GZ, 1990
)
0.28
" Dose-response curves for the relatively specific ligands for the mu-, kappa-, and sigma-receptors were determined using morphine (mu-receptors), dynorphin-(1-13) (kappa-receptors), and N-allylnormetazocine (sigma-receptors)."( Sites of action of mu-, kappa- and sigma-opiate receptor agonists at the feline ileocecal sphincter.
Cohen, S; Ouyang, A; Vos, P, 1988
)
0.27
" Complete dose-response data for morphine, heroin, etorphine, d- and l-ethylketazocine, d- and l-pentazocine, and d- and l-N-allylnormetazocine revealed a predominant response of hyperthermia."( Body temperature effects of opioids in rats: intracerebroventricular administration.
Adler, MW; Geller, EB; Rowan, CH, 1986
)
0.27
" The administration of the lowest dose of EKC stimulated the release of prolactin whereas higher doses were without effect suggesting biphasic dose-response relationship."( Identification of multiple opiate receptors through neuroendocrine responses. I. Effects of agonists.
George, R; Pechnick, R; Poland, RE, 1985
)
0.27
" Comparisons of dose-response curves and efficacies demonstrated that d-NANM was more similar to PCP in its effectiveness in depressing the flexor and skin twitch reflexes than was l-NANM."( Pharmacologic and reinforcing properties of phencyclidine and the enantiomers of N-allylnormetazocine in the dog.
Risner, ME; Shannon, HE; Vaupel, DB, 1986
)
0.27
"Tolerance to the behavioral effects of selected opiate compounds (cyclazocine, ketocyclazocine, naloxone and the stereoisomers of N-allylnormetazocine) and phencyclidine was evaluated using cumulative dosing procedures in rhesus monkeys responding under a fixed-ratio (FR) schedule of food presentation."( Behavioral effects of selected opiates and phencyclidine in the nondependent and cyclazocine-dependent rhesus monkey.
Bergman, J; Hassoun, J; Schuster, CR, 1985
)
0.27
"3 mg/kg) produced a 3-fold shift to the right of the cyclazocine dose-response curve but did not completely block the cyclazocine-like stimulus effects of either SKF 10,047 or ethylketocyclazocine."( Discriminative stimulus effects of prototype opiate receptor agonists in monkeys.
Holtzman, SG; Teal, JJ, 1980
)
0.26
" Dose-response determinations were made for responses to phencyclidine, to a racemic mixture of N-allylnormetazocine, and to the pure levo and dextro isomers of N-allylnormetazocine."( Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats.
Balster, RL; Brady, KT; May, EL, 1982
)
0.26
" Comparisons were made on the basis of dose-response relationships."( Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens.
Morton, EC; Vaupel, DB, 1982
)
0.26
" Dose-response curves were plotted with naloxone against the changes produced by each agonist, and the effect of a number of anticonvulsant drugs on agonist-induced seizures was ascertained."( The epileptogenic spectrum of opiate agonists.
Bearden, LJ; Snead, OC, 1982
)
0.26
" In the present work, using whole-cell patch-clamp techniques in rat retinal slice preparations, we further demonstrate that SKF of higher dosage (50μM) significantly suppressed AMPA receptor (AMPAR)-mediated light-evoked excitatory postsynaptic currents (L-EPSCs) of retinal ON-type GCs (ON GCs), and the effect was reversed by the σR1 antagonist BD1047, suggesting the involvement of σR1."( Activation of the sigma receptor 1 modulates AMPA receptor-mediated light-evoked excitatory postsynaptic currents in rat retinal ganglion cells.
Deng, QQ; Liu, LL; Weng, SJ; Yang, XL; Zhong, YM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1135267Ratio of morphine to compound for analgesic activity in ip dosed mouse1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
N-(2,4,5-Trihydroxyphenehtyl)normetazocine, a potential irreversible inhibitor of the narcotic receptor.
AID148430Ability to induce 50% of maximal effect in rabbit vas deferens expressing Opioid receptor kappa 11983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID148188Relative potency to induce 50% of maximal effect in guinea pig ileum expressing Opioid receptor mu 11983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID148440Relative potency to induce 50% of maximal effect in rabbit vas deferens expressing Opioid receptor kappa 11983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID181512Ability to displace 50% of [3H]- labeled DADLE in rat brain homogenate1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID189558Relative potency in displacing [3H]- labeled DADLE in rat brain homogenate1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID149241Relative potency to induce 50% of maximal effect in mouse vas deferens expressing Opioid receptor delta 11983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID181509Ability to displace 50% of (-) naloxone(1.0) in rat brain homogenate1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID189555Relative potency in displacing (-) naloxone(1.0) in rat brain homogenate1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID149239Ability to induce 50% of maximal effect in mouse vas deferens expressing Opioid receptor delta 11983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID181508Ability to displace 50% of (+/-) ethylketocyclazocine (2.8) in rat brain homogenate1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID189553Relative potency in displacing ((+/-) ethylketocyclazocine (2.8)) in rat brain homogenate1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
AID149726Ability to induce 50% of maximal effect in guinea pig ileum expressing Opioid receptor mu 11983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (491)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990283 (57.64)18.7374
1990's147 (29.94)18.2507
2000's40 (8.15)29.6817
2010's19 (3.87)24.3611
2020's2 (0.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.95 (24.57)
Research Supply Index6.26 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (1.55%)5.53%
Reviews15 (2.91%)6.00%
Case Studies2 (0.39%)4.05%
Observational0 (0.00%)0.25%
Other491 (95.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]